EXPLORE!

USFDA approves Granules India's Losartan Potassium Tablets

  697 Views

#Business And Medicine  #Pathology and Lab Medicine  #Pediatrics  #Pharmacist 

eMediNexus    27 February 2023

The Abbreviated New Drug Application (ANDA) for Losartan Potassium Tablets USP, 25 mg, 50 mg, and 100 mg has been approved by the US Food & Drug Administration (US FDA), according to a statement released by Granules India today.

 

It is bioequivalent to Organon LLC′s Cozaar Tablets, a reference listed drug product (RLD).

 

The US FDA has currently approved 54 ANDAs for granules (52 Final approvals and 2 tentative approvals).

 

For the treatment of hypertension in adults and paediatric patients 6 years of age and older, losartan potassium tablets are recommended since they reduce blood pressure.

 

According to MAT Dec 2022, IQVIA/IMS Health, the current annual U. S. market for losartan potassium tablets is around $336 million.

 

(Source:  https://www.business-standard.com/article/news-cm/granules-india-receives-usfda-approval-for-losartan-potassium-tablets-123022700209_1.html)

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.